Article

Advances in Tardive Dyskinesia: A Review of Recent Literature

In the past three years, the U.S. Food and Drug Administration has approved two medications for tardive dyskinesia, contributing to a resurgent interest in recognition, management, and treatment.

This Psychiatric Times® supplement provides a brief review of primarily recent literature on tardive dyskinesia, including signs and symptoms, risk factors and epidemiology, potential mechanisms, and screening and treatment.

Download Supplement

 

Related Videos
brain connections
1 expert in this video
fly
schism
electric brain
DBS
schizophrenia
happiness
older person
suicide prevention
© 2025 MJH Life Sciences

All rights reserved.